HomeQuestion

What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?

When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?

What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?

Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?

How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

What are strategies to deal with grade 3/4 anorexia associated with Osimertinib? | Mednet